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2. Abbreviations 
Akt   Protein kinase B 
ATP   Adenosine triphosphate 
CFR   Cysteine rich FGF receptor 
D1/D2/D3  Immunoglobulin like domain 1/2/3 
EGF   Epidermal growth factor 
EGFR   Epidermal growth factor receptor 
ER   Endoplasmic reticulum 
ERC   Endocytic recycling compartment 
ERK   Extracellular-signal-regulated kinase 
ESCRT  Endosomal sorting complex required for transport 
FGF   Fibroblast growth factor 
FGFR   Fibroblast growth factor receptor 
FRS2   FGF receptor substrate 2 
Hrs   Hepatocyte-growth-factor-regulated tyrosine kinase substrate 
HSPG   Heparan sulfate proteoglycan 
KGF   Keratinocyte growth factor 
KGFR  Keratinocyte growth factor receptor 
LDL   Low-density lipoprotein 
MAPK  Mitogen-activated protein kinase 
MHC   Major histocompatibility complex 
MVB   Multivesicular body 
NGF   Nerve growth factor 
NLS   Nuclear localization signal 
PDGF   Platelet-derived growth factor 
PKC   Protein kinase C 
PLC   Phospholipase C 
PTB   Phosphotyrosine-binding domain 
RTK   Receptor tyrosine kinase 
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SH2   Src homology domain 
SHP-2  Src homology 2 tyrosine phosphatase 
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3. Aims of the present study 
Fibroblast growth factors and the four related high-affinity, tyrosine kinase fibroblast 
growth factor receptors are involved in the regulation of many key cellular responses 
in developmental and physiological processes. Irregularities in FGF-mediated 
signalling are implicated in several serious disorders such as cancer and various 
forms of dwarfism. Little is known about the fate of endocytosed fibroblast growth 
factors and their receptors and the main purpose of this project is to study and 
compare the intracellular trafficking of the fibroblast growth factor 1 and the four 
related tyrosine kinase fibroblast growth factor receptors upon internalization.  
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4. Introduction 
Uptake of nutrients and communication between cells and their environment occurs 
through the plasma membrane. Several mechanisms for uptake of nutrients and 
molecules that are present in the extracellular milieu have evolved in eukaryotic cells. 
Small molecules such as ions and water enter the cell through plasma membrane 
proteins that form transporters, channels and pumps. Macromolecules that are too 
large to enter the cell through these mechanisms are internalized through 
phagocytosis or pinocytosis. Phagocytosis or cell eating is an active and highly 
regulated process involving ingestion of large particles such as microorganisms and 
dead cells by specific cell-surface receptors and signalling cascades2. Pinocytosis 
occurs in all cells and encompasses several mechanisms by which the cell internalizes 
fluids and solutes from the extracellular milieu into small endocytic vesicles derived 
from the plasma membrane. The endocytic material is then targeted for several 
possible fates including fusion with the endosomal compartments followed by 
degradation or recycling back to the cell surface. The most efficient uptake occurs 
when solutes are captured by specific high-affinity receptors which then become 
concentrated into the endocytic transport vesicles23.  
In addition to supplying the cells with nutrients, endocytosis functions to control 
signalling activity at the cell surface. Cells in the body communicate by secreting 
chemical signals such as hormones and growth factors, which can be recognized by 
specific receptors on recipient cells. Binding of a chemical signal to its receptor may 
induce a variety of different responses in the cell, such as stimulation to divide, 
migrate or differentiate into a different cell type. Cell-surface receptors are key 
elements in cellular communication. To avoid overstimulation of the recipient cell, 
the activated receptors and their corresponding ligands are removed from the cell- 
surface by endocytosis. Upon endocytosis, the signalling from the activated receptors 
attenuates as they are degraded in the lysosomes. Defects in receptor-mediated 
endocytosis including failure to attenuate signalling and impaired delivery of 
 12
endocytosed material, are implicated in several diseases such as cancer55 and 
hypercholesterolemia63. 
4.1 Receptor tyrosine kinases 
Receptor tyrosine kinases (RTKs) are transmembrane molecules positioned at the cell 
surface to detect the presence of corresponding growth factors in the extracellular 
milieu. The binding of a signal protein to the ligand-binding domain on the outside of 
the cell results in formation of a dimer ligand-receptor complex that activates the 
intracellular tyrosine kinase domain of the receptors by autophosphorylation (cross-
phosphorylation). Once activated, the kinase domain transfers a phosphate group 
from ATP to selected tyrosine side chains, both on the receptor proteins themselves 
and on intracellular signalling proteins. These phosphotyrosines can provide docking 
sites for downstream effectors containing Src homology (SH2) or phosphotyrosine-
binding (PTB) domains and initiates a network of signalling pathways that relay cell-
surface signals to the nucleus and other intracellular destinations121.  
These pathways include the extracellular-signal-regulated kinase (ERK)/mitogen-
activated protein kinase (MAPK) pathway, the phospholipase Cγ (PLCγ)/protein 
kinase C (PKC) pathway, the phosphatidylinositol 3-kinase pathway and the 
pathways that regulate small GTPases, such as Rho, Rac and Cdc42121. RTKs have 
also been reported to directly activate signal transducers and activators of 
transcription (STAT) proteins27. The combinatorial information provided by these 
signal transduction pathways can explain the biological responses of cells to growth 
factors. 
4.2 Endocytosis and intracellular sorting of receptor 
tyrosine kinases 
Growth factor-RTK complexes formed at the plasma membrane are not stagnant or 
restricted to the cell surface. The ligand-receptor complexes can be selectively 
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recruited into small areas of the plasma membrane that can invaginate inward and 
pinch off to form vesicles in the cytoplasm. Ligand-RTK complexes are found to be 
internalized through clathrin-mediated endocytosis17,44,54, as well as caveolin-
mediated endocytosis38 and clathrin- and caveolin-independent endocytosis20,21. 
Endocytosis by clathrin-dependent and clathrin-independent mechanisms delivers 
receptors to peripherally located tubular-vesicular structures called sorting or early 
endosomes (Figure 1).  
The sorting endosome is the first main branch point in the receptor-mediated 
endocytic pathway. Molecules in the sorting endosomes can be sorted to late 
endosomes, back to the plasma membrane or to the endocytic recycling compartment 
(ERC) and then back to the surface. The most comprehensive studies of RTK 
endocytosis have been carried out using the epidermal growth factor (EGF) receptor 
as an experimental model. Ligand-free EGF receptors are almost exclusively recycled 
to the cell surface, while ligand-occupied receptors are sorted to lysosomes. However, 
a small fraction of the occupied EGF receptors can also recycle via the ERC or 
directly from sorting endosomes back to the cell surface130. 
The targeting of transmembrane proteins to late endosomes/lysosomes from sorting 
endosomes functions to terminate signalling, as well as to make the cells 
unresponsive to further signal input until a new complement of receptors has been 
synthesized. The attachment of ubiquitin to the cytoplasmic part of a membrane 
protein is thought to function as a signal for lysosomal degradation51,113. Ubiquitin is 
an 8.5 kDa protein that can be covalently linked to lysine residues, and ubiquitination 
was first described as a mechanism for targeting cytosolic proteins for degradation by 
the proteasome. Poly monoubiquitination of the EGF receptor has been shown to be 
necessary for both internalization of the receptor and also for targeting the protein to 
invaginated membranes in sorting endosomes51. Hrs (hepatocyte-growth-factor-
regulated tyrosine kinase substrate) links the ubiquitinated receptors to flat clathrin 
lattices on endosomes111,112,114 and this interaction might be important for retaining 
ubiquitinated receptors in maturating endosomes, which would lead to their delivery 
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to late endosomes. In a second sorting step, the ESCRT (endosomal sorting complex 
required for transport) protein complexes have been shown to recognize and sort 
ubiquitinated proteins for delivery to the vacuole lumen65. The ESCRT complexes 
were first identified in yeast, but the emerging picture provides an evolutionary 
conserved function of the ESCRT complexes in targeting of receptors for down-
regulation also in mammalian cells.  
The endosomal intermediates between sorting and late endosomes, in which small 
vesicles are enclosed within an endosomal membrane, are called multivesicular 
bodies (MVBs)49,83. MVBs are transported along microtubules towards late 
endosomes, with which they eventually fuse4. In contrast to MVBs that are typically 
spherical, late endosomes are highly pleiomorphic with cisternal, tubular and 
multivesicular regions. Also their protein/lipid composition is distinct from that of 
MVBs. Late endosomes also function as an important sorting station in the endocytic 
pathway. The mannose-6-phosphate receptor cycles from late endosomes back to the 
Golgi network39 whereas molecules of class II major histocompatibility complex 
(MHC) are transported from late endosomes to the plasma membrane in maturing 
dendritic cells25. Receptors in the degradative endosomal pathway are sorted from 
late endosomes to lysosomes. Along the endocytic pathway, the intravesicular pH 
drops from pH 6.0-6.5 in sorting endosomes to pH 4.5-5.5 in late endosomes and the 
pH reaches 4-5 in lysosomes. Both the low internal pH and the degradative enzymes 
within the membrane-bounded organelles make the lysosomes the site of degradation 
of proteins in the endocytic pathway. 
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Figure 1. Receptor mediated endocytosis. Upon internalization the 
receptors appear in sorting endosomes. At the sorting endosomes, 
receptors that are destined to be degraded in the lysosomes become 
ubiquitinated, recognized by Hrs and the ESCRT complexes and 
invaginated into the endosomes. Receptors that are not retained in the 
sorting endosomes recycles either directly or via the endocytic recycling 
compartment, ERC, back to the cell surface. Endosomes containing 
proteins in internal vesicles are referred to as multivesicular bodies, MVBs. 
MVBs fuse with late endosomes and the endocytosed material is then 
sorted from the late endosomes to the lysosomes. Materials are also 
transported between the Golgi apparatus and the late endosomes and 
between the Golgi apparatus and the ERC. 
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The role of RTK endocytosis might extend beyond controlling signalling activity at 
the cell surface. It has become clear in recent years that many activated tyrosine 
kinase-coupled transmembrane receptors continue to propagate signals after 
internalization, and that lysosomal degradation may be required to terminate 
signalling131. Classical studies of endocytosis of low-density lipoprotein (LDL) 
implied that the ligand dissociates from the receptor in the acidic environment of 
endosomes so that the ligand and the receptor are sorted differently42. However, it 
was found that receptor-ligand complexes of RTKs, such as EGF, platelet-derived 
growth factor (PDGF) and nerve growth factor (NGF), do not significantly dissociate 
at endosomal pH129,132,146. Consequently, a great amount of these receptors remain 
ligand-bound in endosomes. The preservation of ligand-receptor complexes results in 
the existence of a pool of receptors that remains dimerized and thereby potentially 
active. Tyrosine phosphorylation and kinase activity of internalized receptors was 
first shown for EGF and insulin receptors and later reported for other RTKs6,129. RTK 
mediated signal transduction is accomplished by cascades of protein-protein 
interactions. Consistent with the presence of phosphorylated internalized receptors, 
several receptor-interacting proteins are found in endosomes131. 
It has also been reported that the intracellular part of EGF receptors can be 
proteolytically cleaved under binding of ligand and that fragments of the receptors 
can then be transported directly to the nucleus95. The more controversial observation 
that full length tyrosine kinase receptors can travel from the plasma membrane to the 
nucleus and possibly signal inside the nucleus has been reported from several 
groups78,141. In addition, exogenous growth factors have also been found to 
accumulate in the nucleus or in the cytosol3,79,97,115,142. However, the process of 
translocation and the possible function of growth factors, receptors and fragments of 
the receptors in the nucleus are still poorly understood. 
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4.3 Fibroblast growth factors 
Genes, transcripts and proteins of the fibroblast growth factor superfamily have been 
identified in invertebrates as well as in vertebrates24,94. Defining features of the family 
are a strong affinity for heparin and heparan sulfate15, and a highly homologous 
central core of 120 amino acids148. The family comprises 22 structurally related 
polypeptides in humans100,108 encoded by distinct but evolutionary related genes34,99, 
ranging in molecular mass from 14 to 34 kDa and sharing 13-71% amino acid 
identity100. Further diversity in the protein family is generated through the use of 
alternative translation initiation sites within the messenger RNA31 as well as 
alternative splicing103,139,150. The crystal structure of the prototypic FGF family 
members, FGF1 and FGF2 has been shown to consist of twelve antiparallel β strands 
arranged to form a cylindrical β-barrel closed by the more variable amino- and 
carboxy-terminal streches148. 
FGF1, FGF2, FGF9 and FGF11-141,61,84,127, as opposed to other FGFs, lack a signal 
sequence required for secretion through the classical endoplasmic reticulum-Golgi 
apparatus pathway. FGF11-14 are believed to remain intracellular127, while FGF1, 
FGF2 and FGF9 are released from the cells by a mechanism different from the 
classical ER-Golgi secretory pathway. Secretion of FGF1 is elevated under several 
stress conditions, such as hypoxia, serum starvation or heat60,91,124. Released FGF1 is 
unable to bind heparin and exist as an inactive homodimer in complex with the 
calcium binding protein, S100A13 and the extravesicular domain of synaptotagmin, a 
transmembrane component of synaptic vesicles75,136. Despite the structural and 
functional similarity between FGF1 and FGF2, the peptides may utilize distinct ER-
Golgi independent secretory pathways. FGF2 is not secreted in response to heat 
shock and vesicle shedding has been proposed as a possible secretion 
mechanism82,137. Recently, there was reported that secretion of FGF2 did not require 
protein unfolding7. 
Accumulating evidence indicates that FGF1, FGF2 and FGF3 can act intracellularly 
as well as extracellularly12,58,66. Exogenous FGF1 and FGF2 are able to translocate to 
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the cytosol and the nucleus. Evidence for membrane translocation of exogenous 
FGF1 and FGF2 have been obtained by farnesylation studies of a growth factor 
mutant that contains a C-terminal farnesylation signal, a CAAX-box. Since the 
farnesyl transferase is located only in the cytosol and the nucleus22, farnesylation of 
an externally added CAAX containing protein indicates its translocation across the 
cellular membrane. This was demonstrated for both FGF1142 and FGF279. In another 
approach, phosphorylation of exogenous FGF1 by protein kinase C, an enzyme 
exclusively present in the cytosol and the nucleus, demonstrated membrane 
translocation of the growth factor67. Localization to the nucleus appears to depend on 
the presence of a nuclear localization sequence (NLS) within the growth 
factors58,66,110. It has been suggested that nuclear FGF1 is involved in a mechanism of 
regulation of DNA-synthesis67. However, the best described signalling mechanism 
induced by external FGFs is the signalling mediated through binding to high-affinity 
cell-surface receptors (FGFRs) that possess tyrosine kinase activity121.  
4.4 Fibroblast growth factor receptors 
4.4.1 High-affinity  FGF receptors (FGFRs) 
The fibroblast growth factor receptor family comprises a variety of polypeptides 
encoded by five closely related genes. FGFR1-4 have a conserved overall structure, 
sharing up to 72% identity. FGFR1 and FGFR2 are most similar, while FGFR1 and 
FGFR4 are least similar62. The fifth member of the gene family does not contain a 
tyrosine kinase domain but still share 32% identity within the extracellular part with 
the other FGF receptors126.  Additional diversity among the receptors is generated by 
alternative splicing of receptor 1-3, resulting in a variety of receptor isoforms62.  
The prototypical FGF receptor consists of an extracellular domain, a single 
transmembrane domain and an intracellular domain62 (Figure 2). The extracellular 
domain contains two or three immunoglobulin like domains (D1-D3), dependent on 
alternative splicing. Between D1 and D2 is a unique acidic region referred to as the 
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acidic box. D2 contains a heparin binding domain64. In addition, a signal peptide at 
the amino-terminus is cleaved off after translocation of the newly synthesized 
receptor into the endoplasmic reticulum. The intracellular part of the receptor 
contains a juxtamembrane stretch, a split tyrosine kinase 
domain and a C-terminal tail.  
Different exon usage results in receptors which may be 
truncated, lack immunoglobulin like domains, or utilize 
different coding regions for the same Ig-like domains. One 
of the most important mechanisms by which FGFRs 
determine specificity for different FGFs is by alternate exon 
usage of the membrane proximal half of the D3. The exons 
encoding the membrane proximal half of D3 are designated 
IIIa, IIIb and IIIc. Such alternative splicing events are 
regulated in a tissue-specific manner. Usually, the 
expression of version IIIb is restricted to epithelial cells and 
IIIc to mesenchymal cells 8,101. 
4.4.2 Low affinity FGF receptors 
A common feature of FGFs and several other growth factors is a remarkable affinity 
for heparin and cell-surface heparan sulfate proteoglycans (HSPGs). Heparin and 
heparan sulfate are common glycosaminoglycans in proteoglycans. Heparan sulfate 
contains low and highly sulfated sites while heparin is more uniformly highly 
sulfated34. Unlike cell-surface tyrosine kinase receptors, HSPGs are not able to 
transduce any signal, but they can function as modulators of growth factor 
activities119. 
Binding of FGFs to HSPGs presented at the cell surface and in the extracellular 
matrix protects them from inactivation by heat and acid46. Another effect of HSPG 
binding in the extracellular milieu is the protection of the growth factors from 
proteolytic degradation by circulating proteases such as trypsin and plasmin120,128. 
Figure 2. The 
prototypical FGFR. 
The membrane 
proximal half of D3 
is indicated in grey 
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Binding of FGFs to HSPGs also creates a local reservoir of FGFs that can be released 
by extracellular enzymes capable of degrading the proteoglycans59. Furthermore, 
binding of FGFs (and FGFRs) to heparins/HSPGs plays an important role in the 
formation of stable FGF-FGFR complexes at the cell surface57. 
4.4.3 Cysteine-rich FGF receptor 
Various FGFs bind with high affinity also to a cysteine rich FGF receptor (CFR)16. 
The CFR lacks tyrosine kinase activity and does not belong to the FGFR family. 
Although reports indicate that CFRs are involved in intracellular regulation of FGF 
secretion70 their function are generally unknown. CFR binds FGF in a heparin 
independent manner, but exhibit high affinity for HSPGs149. The full-length form of 
CFR is primarily located in the Golgi apparatus, while a proteolytically cleaved 
derivative has also been found secreted and deposited in the extracellular matrix43.  
4.5 Signalling from high-affinity fibroblast growth factor 
receptor 
FGF binding to and dimerization of the specific tyrosine kinase receptor is a more 
complex process than in the case of other growth factors. FGF binds the FGFR in the 
D2-D3 junction, and heparin is involved in bridging and stabilizing two FGF/FGFR 
complexes in a receptor dimer106,107,123. Although HSPGs generally are required for 
formation of stable FGF/FGFR signalling complexes, activation of FGFRs by FGFs 
in the absence of HSPGs has also been reported29. Two forms of the growth 
factor/receptor-signalling complex can then exist, a less stable FGF/FGFR (2:2) 
complex and a more stable FGF/FGFR/HSPG (2:2:2) complex with prolonged 
signalling activity99. The FGF/FGFR/HSPG complex has also been proposed to 
assemble around one central heparin molecule, linking two FGFs into a dimer that 
bridges between two receptor chains (2:2:1)104. Since FGFRs also contain a heparin-
binding site in D2 involved in formation of the signalling complex64,107, it is not 
excluded that heparans could induce FGFR dimerization and activation without the 
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growth factor35. It has been proposed that 
D1 and the acidic box between D1 and D2 
act cooperatively to negatively regulate 
FGFR function by competing with FGF 
and heparin for FGFR binding96,122. In this 
way D1 and the acidic box might play an 
autoinhibitory role, regulating binding of 
heparans and FGF to FGFR. 
The dimerization of FGFRs by FGFs 
results in activation of the intrinsic 
tyrosine kinase and autophosphorylation 
of tyrosine residues in the intracellular 
part of the receptor. The phosphorylated 
tyrosine residues serve as binding sites for SH2 and PTB domain-containing 
signalling molecules. These molecules often possess an enzymatic activity (PLC-
γ)14,85 or are adaptor molecules (Shc, FRS2, Shb, Crk)69 that associate with other 
signalling enzymes which in turn are either positive or negative regulators of FGF 
signalling50,73,73,76,143 (Figure 4). 
PLC- γ/PKC, PI 3-Kinase/Akt and Ras/MAPK are three major downstream signalling 
pathways activated by FGFs11 (Figure 4). Grb2, a small adaptor protein, binds 
directly to FRS2 or Shc, both of which are phosphorylated on tyrosines by the 
activated FGFR, and recruits the nucleotide exchange factor, Sos to the plasma 
membrane. Sos catalyzes the exchange of GDP for GTP on Ras and thereby promotes 
the activation of Ras and the MAP kinases, Erk1 and Erk2 downstream of Ras69. PI 
3-kinase seems to be directly bound to Gab1, which is also recruited by Grb2 to the 
FRS2/receptor complex98. Activated PI 3-kinase phosphorylates phosphatidylinositol 
4,5 bisphosphate (PI(4,5)P2) , generating phosphatidylinositol 3,4,5 trisphosphate  
Figure 3. FGFR activation 
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Figure 4. Signalling pathways activated by FGFRs 
(PI(3,4,5)P3). The PI(3,4,5)P3 serves as a docking site for signalling proteins such as 
Akt121. It has also been reported that FRS2 could link FGFR activation to atypical 
PKC isoforms77. PLCγ on the other hand binds directly to the FGFR and becomes 
tyrosine phosphorylated and active upon binding14,85, leading to hydrolysis of 
PI(4,5)P2 to inositol 1,4,5 trisphosphate (IP3) and diacylglycerol. IP3 generation leads 
to release of Ca2+ from internal stores, whereas diacylglycerol activates members of 
the protein kinase C family (PKC)121. 
When Grb2 is bound to Sprouty1 and Sprouty2, which are translocated to the plasma 
membrane and become phosphorylated upon FGF stimulation, the recruitment of 
Grb2-SOS to FRS2 is inhibited53. The transmembrane protein Sef was found to 
inhibit FGF induced proliferation by interaction with the FGFR74. The 
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phosphotyrosine phosphatase SHP-2, activated through binding to FRS2 is involved 
in regulation of signal transduction downstream of tyrosine kinases69. 
Several cytoplasmic kinases are also activated or inactivated by FGFR stimulation. A 
serine kinase, p85, has been shown to associate with activated FGFR4, implicating a 
role for serine phosphorylation in signal transmission by the receptor138. FGFR1 can 
stimulate or inhibit the Src kinase activity in a PKC-dependent manner69 and the 
kinase is involved in a variety of signalling cascades in FGF stimulated cells144. FAK 
another cytoplasmic tyrosine kinase is also activated by FGF stimuli105. The adaptor 
proteins Crk and Shb are phosphorylated on tyrosines by the activated FGFR and 
provide additional docking sites for downstream signalling molecules69. 
The signalling pathways activated by FGFRs seem to include various signalling 
molecules. However, further investigations will be necessary to reveal the complete 
picture of FGFR signalling and the specificity of the induced signals. 
4.6 Endocytosis and intracellular sorting of the FGF/FGFR 
complex 
FGF is rapidly internalized after binding to its high-affinity receptor29,33,81. The 
endocytic process of FGFs/FGFRs has been described in a few studies and it appears 
that the different FGFRs and their isoforms may take different pathways and that this 
also may vary between different cell types. 
FGF7 (KGF) bound to FGFR2 (IIIb) (KGFR) has been shown to be taken up by 
clathrin mediated endocytosis in NIH/3T3 cells stably transfected with KGFR, as 
well as in A253 carcinoma cells and in human cultured karatinocytes81. However 
FGF1/FGFR4 was reported to be endocytosed mainly by a mechanism different from 
the clathrin mediated pathway and caveolae in COS cells21. In HeLa cells 
FGF1/FGFR4 was reported to be endocytosed partly by a clathrin dependent 
pathway, partly by a non-clathrin/non-caveolae mechanism20. FGF2 has been 
reported to be endocytosed mainly through caveolae in BHK cells and ABAE cells 
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expressing endogenous FGF receptors38. The signals within the FGFR that mediate 
endocytosis are not well defined, but phosphorylation events induced by the tyrosine 
kinase appear to be important for efficient endocytosis20,92,133. 
Irrespective of their mechanism of internalization, after endocytosis, the FGF/FGFR 
complexes are shown to enter early endosomes/sorting endosomes21,38. Subsequent to 
their presence in sorting endosomes, FGF7/FGFR2 (IIIb) was found to be sorted to 
late endosomes in HeLa cells9 and FGF2 has also been shown to be sorted to late 
endosomes/lysosomes in BHK cells38. On the other hand, FGF1/FGFR4 was sorted 
mainly to the recycling compartment in COS cells and in HeLa cells21. This transport 
was apparently regulated by the receptor kinase, as a kinase dead mutant of FGFR4 
showed increased transport to lysosomes20. 
Degradation of internalized FGF receptors has been observed after a few hours9,90,133. 
It has been shown that binding of FGF to FGFR1 and FGFR3 induces ubiquitination 
of the receptors and that this contributes to down-regulation of the receptor86,87,143. 
The FGFR was found to recruit the ubiquitin ligase Cbl by an indirect mechanism 
involving the docking protein FRS2 and Grb2143. Activated FGFR3 has recently been 
reported to be targeted for lysosomal degradation through c-Cbl-mediated 
ubiquitination while FGFR3 harbouring mutations associated with achondroplasia 
and thanatophoric dysplasia types II (TDII) has been reported to escape lysosomal 
targeting19. 
RTK signalling does not only occur at the plasma membrane, but also from 
internalized ligand/receptor complexes. FGF7/FGFR2 were found to remain 
associated in active complexes through the endocytic pathway9,81, and activated 
FGFR4 was found in the recycling endosomal compartment21. 
Internalized FGF1 is unusually long lived10,89. In various cell types only 10-30% of 
the internalized growth factor was found to be degraded after 6-8 hours20,92 and FGF1 
can still be detected 24 hours after internalization32,48.  
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Accumulating evidence for cell-entry of exogenous FGF1 and FGF2 indicates that 
they can act intracellularly as well as extracellularly97. FGF1 and FGF2 activate not 
only the cell-surface receptors, but in addition, the receptor-bound growth factor is 
endocytosed and translocated across the membrane to reach the cytosol and the 
nucleus67,79,142. Recently obtained data have shown that translocation of the growth 
factor to the cytosol occurs from the lumen of intracellular vesicles and that the 
translocation process of internalized FGF1 requires electric potential across the 
vesicular membrane, generated by vacuolar proton pumps80. Translocation of FGFs 
has been reported in NIH/3T3 cells, HUVE cells, CPAE cells expressing endogenous 
FGFRs80, and in COS cells transiently transfected with FGFR468. 
It has also been reported that FGF2 stimulation induces nuclear translocation of 
FGFR178. The nuclear import of FGFR1 is mediated by importin β, and was found to 
play a role in the regulation of the cell cycle41,117. It has been suggested that the 
association of the FGFR1 transmembrane region with the ER membrane could be 
relatively unstable and that the nucleus-destined receptor could be released from the 
ER/Golgi membranes into the cytosol before delivery to the plasma membrane93. 
However, receptors that have been present at the cell surface have also been reported 
to be transported into the nucleus. 
Binding of FGFs to surface HSPGs can also leads to FGF internalization118. FGF1 
and FGF2 internalized by binding to HSPGs was shown to be sorted to 
lysosomes20,37.  
4.7 Biological function of fibroblast growth factors 
The first members of the FGF family were discovered in brain and pituitary extracts 
due to their growth-promoting activity on fibroblasts5,45. This activity turned out not 
to be specific for cultured fibroblasts, but could be observed on a variety of cell 
lines47. The list of biological activities attributed to FGFs has also been considerably 
extended and their ability to mediate a wide variety of biological responses is 
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probably the most remarkable feature of FGFs135. Biological responses to FGF 
signalling are depending on the target cell type, tissue context and the environment of 
the site where the signalling occurs.  
FGF receptors can stimulate or inhibit cell proliferation depending on cell type. In 
mesoderm and ectoderm derived cells FGF signalling stimulate cell proliferation47, 
whereas proliferation is inhibited by FGF signalling in chondrocytes116. Nuclear 
localization of FGF3 showed inhibitory effects on cell growth in mammary epithelial 
cells66. FGF stimulation can also induce apoptosis in certain cases. The induction of 
cell death by exposure to FGF2 is associated with a G1 cell cycle arrest and activation 
of initiator and effector caspases13. On the other hand FGFs have also been shown to 
delay apoptosis in various cell lines by upregulated expression of the antiapoptotic 
protein, bcl-271. FGFR signalling is found to be critical for cell migration as cells 
introduced to a dominant negative mutant of FGFR1 were unable to migrate102.  FGF 
signalling is also implicated in cell differentiation26,47,50. 
FGFs play important roles in development40. They are well known inducers of 
mesoderm62 and they have also been shown to be relevant in organogenesis, 
particularly in that of the nervous system, the lungs and the limbs108. FGFs are also 
believed to be important in wound healing, in which formation of new blood vessels 
is a significant part of the process15,33. 
4.8 FGF implicated in human disorders 
Up-regulation of FGFs/FGFRs and structural alterations in genes encoding FGFRs 
are found in a number of human cancers, and FGFs and the FGF signalling pathways 
appear to play important roles in tumour development and progression. The growth 
factor can directly promote tumour cell growth due to their mitogenic, antiapoptotic 
and angiogenetic activity33,108. Angiogenesis, the formation of new blood vessels 
from existing ones, is required for a tumour to grow beyond the size where diffusion 
of nutrients and waste products can keep the tumour cells alive. Angiogenesis is also 
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crucial for metastatic progression. FGF1 and FGF2, together with vascular 
endothelial growth factors, are considered as the most common tumour angiogenic 
factors147. 
Dysregulation of FGF signalling in cancer arising from an increased availability of 
FGFs is a result of overexpression of different FGFs or uncontrolled release of FGFs 
sequestered in the extracellular matrix108. FGFs have been shown to be up-regulated 
in various forms of cancer such as human pancreatic cancer, breast cancer, renal 
cancer and some prostate cancers52,72  
Dysregulation of FGF signalling as a result of alterations at the level of the receptor 
has been shown to occur through inappropriate expression, point mutations, splice 
variations and genomic alterations108. FGFRs have been found overexpressed in 
several human tumour samples such as brain tumours, breast tumours, pancreatic 
cancer and prostate cancer36,72,88,145. The tumour promoting effect of FGFR 
overexpression seems to depend on the target cell type and tissue context. In prostate 
cancer, overexpression of FGFR1 accelerates tumorgenesis whereas FGFR2 in these 
tumours inhibit malignant progression30. Mutations in FGFRs resulting in 
constitutively active forms of the receptors have also been mapped in several human 
cancers.  Activating mutations in FGFR3 have been implicated in human multiple 
myeloma and bladder cancer18,125. Alternative spliced forms of the receptors may also 
play significant roles in human cancers. A soluble, spliced variant of FGFR3 is found 
frequently expressed in tumour cells and tissues such as neuroblastoma, bladder 
carcinoma, breast carcinoma, colorectal carcinoma and tumours of the Ewing’s 
sarcoma family and appears to contribute to malignant transformations134 and a N-
terminally truncated isoform of FGFR4 have been implicated in pituitary 
tumorgenesis in a majority of human pituitary adenomas109. 
A large number of human skeletal disorders such as various forms of dwarfism have 
been mapped to mutations in genes encoding FGFR1-328. These are syndromes where 
either growth of the long bones is affected (chondrodysplasia) or fusion of the cranial 
structures is premature (craniosynostosis). Common for most of the FGFR mutations 
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found in these disorders are that they cause ligand-independent activation of the 
receptor kinase. In several cases the mutation creates a free cysteine-residue in the 
extracellular part of the receptor, believed to form intermolecular disulfide bonds and 
promote dimerizing and thereby ligand-independent activation of the receptor 
tyrosine kinase140. Mutations in the transmembrane domain are thought to facilitate 
intermolecular hydrogen bonds, also leading to ligand independent receptor 
dimerization140. Directly activation of the receptors through mutations in the kinase 
domain is also found in several forms of skeletal disorders140. Enhancement of FGF 
binding affinity56 and escaping lysosomal targeting19 are also observed properties of 
FGFRs harbouring skeletal disorder mutations.  
4.9 Perspectives 
The FGFs and their high-affinity receptors clearly play important roles in the 
development and growth of the organism. Since the signalling through FGFs appears 
to be fundamental in so many different processes and irregularities in FGF-mediated 
signalling are implicated in several serious disorders, the basic biology of FGFs, 
FGFRs and their signalling is of great interest. Much effort has concerned the 
elucidation of the biological responses to FGF signalling, whereas the cell biology of 
FGFs and their receptors is less studied.  Knowledge about how growth factors and 
corresponding receptors function is crucial in order to try to stimulate or inhibit their 
effects for therapeutical purposes. Therefore, studies on the basic biology of FGFs, 
FGFRs and their signalling might lay the basis for future clinical applications. 
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Different intracellular trafficking of FGF1 endocytosed by 
the four specific FGF receptors 
Ellen Margrethe Haugsten, Vigdis Sørensen*, Sjur Olsnes and Jørgen Wesche 
The Institute for Cancer Research, The Norwegian Radium Hospital, Montebello, 
0310 Oslo, Norway 
The sorting of internalized fibroblast growth factor 1 (FGF1) was studied in HeLa 
cells transfected with either of the four spesific FGF receptors, (FGFR1-4). Fifteen 
min after endocytosis, externally added FGF1 bound to either receptor was localized in 
sorting/early endosomes. Subsequently, FGF1 internalized via FGFR1-3 localized 
mainly to late endosomes/lysosomes, in a similar way as endocytosed EGF. On the 
other hand, FGF1 internalized via FGFR4 was found to mainly follow the same 
intracellular pathway as the recycling ligand transferrin. Furthermore, FGF1 
endocytosed by FGFR4 was more slowly degraded than FGF1 endocytosed by 
FGFR1-3. In addition, internalized FGFR4 as such was more slowly degraded than the 
other receptors. The data indicate that after endocytosis FGFR4 is sorted mainly to the 
recycling compartment while FGFR1-3 are sorted to degradation in the lysosomes. By 
aligning the amino acid sequence of the intracellular part of the four FGF receptors, 
several lysines that are conserved in FGFR1-3 but not in FGFR4 were revealed. 
Lysines are potential ubiquitination-sites and could thus target a receptor for sorting to 
lysosomes. Indeed, we found that FGFR4 is less ubiquitinated than FGFR1 after 
internalization, which is possibly the reason for the different sorting of the receptors. 
                                              
* The experiment presented in Figure 6 was performed by Vigdis Sørensen. 
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Introduction 
Many growth factors and cytokines can bind to more than one receptor, but in many 
cases the different roles of the separate receptors in signal transduction are unclear. 
Intracellular sorting of ligand-receptor complexes may determine their signalling and 
we have here studied the cellular trafficking of ligand bound to receptors for fibroblast 
growth factors (FGFs).  
The large family of FGFs comprises 22 structurally related heparin binding 
polypeptides which are involved in the regulation of various cellular responses in 
developmental and physiological processes30. The FGFs mediate their biological 
effects through binding to high-affinity cell-surface receptors, FGFRs. The FGFR 
family constitutes a variety of polypeptides encoded by four closely related genes18. 
The receptors share common structural features and consist of an extracellular ligand 
binding domain, a transmembrane domain and a cytosplasmic region. The extracellular 
domain contains a unique acidic region and two or three immunoglobulin like domains 
(D1-D3), dependent on alternative splicing. The cytoplasmic region contains a split 
tyrosine kinase domain18.  
Binding of FGFs to FGFRs is stabilized by heparan sulfate proteoglycans (HSPGs) 
and results in a dimer receptor-ligand complex that activates the intracellular tyrosine 
kinase domain by autophosphorylation. The autophosphorylation triggers the transient 
assembly of a large intracellular complex, which activates downstream signalling 
pathways such as PLC- γ/PKC, PI 3-Kinase/Akt and Ras/MAPK2. Depending on the 
target cell type, FGF signalling can induce cell proliferation, cell growth arrest, cell 
differentiation, apoptosis and cell migration2,3,13. 
Signalling from activated transmembrane receptors is attenuated by degradation in 
lysosomes. Lysosomal targeting of tyrosine kinase receptors is best illustrated for the 
epidermal growth factor receptor (EGFR) and involves the attachment of ubiquitin to 
lysine residues in the cytoplasmic tail of the activated receptor33. Upon internalization, 
the receptors appear in early/sorting endosomes where the receptors that are destined 
to be degraded in the lysosomes become ubiquitinated, recognized by Hrs and the 
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ESCRT complexes and internalized into the endosomes by membrane invagination32. 
Endosomes containing internal vesicles are referred to as multivesicular bodies, 
MVBs. MVBs fuse with late endosomes and the endocytosed material is then sorted 
from late endosomes to lysosomes where it is degraded.  
Receptors that are not retained in the sorting endosomes recycle either directly or via 
the endocytic recycling compartment, ERC, back to the cell surface. Most receptors 
known to recycle possess no signalling activity and are often associated with uptake of 
nutrients. The transferrin receptor, TfR, is known to recycle via the ERC and is often 
used as a marker for the recycling endocytic pathway42. The transferrin receptor binds 
its ligand, diferric transferrin and is rapidly internalized. In the acidic environment of 
sorting endosomes the two iron ions are released from the ligand and transported into 
the cytoplasm, whereas the ligand/receptor recycles via the ERC to the cell surface. At 
the neutral extracellular pH, iron-free transferrin is released from the receptor7. The 
importance of ubiquitin as a signal for lysosomal sorting was illustrated when 
transferrin receptors fused to ubiquitin was found to be sorted into the degradative 
pathway31. 
From what is known about the endocytosis of FGFRs, it appears that they may utilize 
different mechanisms for internalization and that this also may vary between different 
cell types5,6,11,22. However, irrespective of the mechanism of endocytosis, FGF/FGFR 
complexes have been observed in early endosomes/sorting endosomes approximately 
10 min after internalization1,6,11. Subsequent to their presence in sorting endosomes, 
KGF/KGFR (FGF7 and a splicing variant of FGFR2), was found to be sorted to late 
endosomes in HeLa cells1. FGF2 has also been observed in late endosomes and 
lysosomes in BHK cells11. On the other hand, FGF1/FGFR4 in COS cells has been 
found to accumulate in a juxtanuclear region, identified as the recycling compartment6. 
It was found that binding of FGF to FGFR1 and FGFR3 induces ubiquitination of the 
receptors and that this contributes to their downregulation4,23,24,40. Activated FGFR3 
has recently been reported to be targeted for lysosomal degradation through c-Cbl-
mediated ubiquitination while FGFR3 harbouring mutations associated with skeletal 
disorders were found to be less ubiquitinated and escape lysosomal targeting4. 
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In order to compare the intracellular fate of the four related FGFRs upon 
internalization, HeLa cells transfected with either of the four FGFRs, were chosen as a 
model system, and FGF1, which binds equally well to the four FGFRs29 was used as a 
ligand. The present work demonstrates that the four receptors are indeed sorted 
differently and that different levels of ubiquitination appear to be the molecular 
mechanism responsible for the different sorting. 
Materials and methods 
Materials 
Antibodies: Rabbit anti-FGFR1, anti-FGFR2, anti-FGFR3 and anti-FGFR4 antibodies 
were from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit antibodies against 
tyrosine 653/654 phosphorylated FGFRs were from Cell Signalling (Beverly, MA). 
Mouse anti-EEA1 antibodies were obtained from Transduction laboratories 
(Lexington, KY) and mouse anti-LAMP-1 antibodies were from Developmental 
Studies Hybridoma Bank, (Iowa City, IA). Mouse anti-myc antibodies were from 
9E10 hybridoma (Evan, Lewis, Ramsay 1985). Mouse anti-TfR antibodies were from 
Boehringer Mannheim (Mannheim, Germany). The secondary antibodies Cy2-
conjugated anti-mouse IgG, Cy2-conjugated anti-rabbit IgG, HRP-conjugated anti-
mouse IgG and HRP-conjugated anti-rabbit IgG were from Jackson Immuno-Research 
Laboratories (West Grove, PA).  
Chemicals: Cy3-maleimide, Cy5-monofunctional reactive dye, heparin-Sepharose, 
streptavidin-Sepharose, ECL plus Western blotting system were from Amersham 
Biosciences (Buckinghamshire, UK). APS, TEMED, 40% Acrylamide/Bis-acrylamide 
and Restore Western Blot Stripping Buffer were from BIO-RAD (Hercules, CA). 
Fugene 6 was from Boehringer Mannheim (Indianapolis, IN). DMEM, streptomycin 
and penicillin were from GIBCO, Invitrogen (Carlsbad, CA). Alexa 488 EGF was 
from Molecular Probes, Invitrogen. Restriction enzymes were from New England 
Biolabs, (Beverly, MA). Mowiol was from Novabiochem Corporation (La Jolla, CA). 
Fetal calf serum was from PAA Laboratories GmbH (Linz, Austria). Easytag 
Methionine L-[35S] was from Perkin Elmer (Boston, MA). Leupeptin to use on live 
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cells was from Peptide Institute Inc (Osaka, Japan). Ez-link sulfo-NHS-LC-Biotin was 
from Pierce (Rockford, IL). Rabbit Reticulocyte Lysate System was obtained from 
Promega Corporation (Madison, WI). Complete EDTA free Protease Inhibitor cocktail 
tablets were from Roche Diagnostics (Penzberg, Germany). T7 RNA polymerase was 
from Stratagene (La Jolla, CA). Other chemicals were from Sigma-Aldrich (St. Louis, 
MO).  
Equipments: Cell culture plates were from BD Biosciences (San Jose, CA) and Nalge 
Nunc International (Rochester, NY). Immobilon-P PVDF membrane was from 
Millipore Corporation (Bedford, MA). QIAshredder columns were from QIAGEN 
(Hilden, Germany). Zeiss LSM 510 META confocal microscope and Zeiss LSM 
Image Browser (Version 3) were from Zeiss (Jena, Germany). Adobe Photoshop 7.0 
was from Adobe (San Jose, CA). STORM gel and blot imaging system and Image 
Quant, Version 5.0 were from Molecular Dynamics, Amersham Biosciences 
(Buckinghamshire, UK). Chemi Genius Image Acquisition System was from Syngene 
(Camebridge, UK). Recombinant FGF1 was a generous gift from Dr. Antoni 
Wiedlocha, Institute for Cancer Research, The Norwegian Radium Hospital. 
Plasmids 
pcDNA3-hFGFR1: cDNA encoding hFGFR1 IIIc was cut out from pSV7d39 with 
EcoRI and XbaI in two fragments, and ligated into pcDNA3 (Invitrogen, Carlsbad, 
CA) cut with the same enzymes. pcDNA3-hFGFR2: cDNA encoding hFGFR2 IIIc 
lacking D1 was cut out from pBluescript (RZPD, Berlin, Germany, Clone ID: 
IMAGp998N0911701Q3) with NotI and SpeI, and ligated into pcDNA3 cut with NotI 
and XbaI. The pcDNA3-hFGFR3 construct was a generous gift from Dr. Avner 
Yayon, ProChon Biotech Ltd., Israel. The pcDNA3-hFGFR4 construct has been 
described earlier19. The pcDNA3-myc-tagged-ubiquitin was a generous gift from Dr. 
Harald Stenmark, Institute for Cancer Research, The Norwegian Radium Hospital. The 
pTriEX-2-FGF1 construct was a generous gift from Camilla Skiple Skjerpen, Institute 
for Cancer Research, The Norwegian Radium Hospital. 
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Cells 
HeLa cells were propagated in Dulbecco’s Modified Eagle Medium, DMEM, 
supplemented with 10% (vol/vol) fetal calf serum and 100 U/ml penicillin and 100 
µg/ml streptomycin in a 5% CO2 atmosphere at 37°C. 
Transfections 
Transient expression of the different receptors was performed by transfecting HeLa 
cells with the plasmid DNA (pcDNA3 with appropriate inserts) by using Fugene 6 
transfection reagent according to the manufacturer’s protocol. Cells were seeded into 
plates the day preceding the transfection and experiments were performed 15-24 hours 
after transfection. 
Laser scanning confocal microscopy 
Following the manufacturer’s protocol, FGF1 was labelled with Cy3-maleimide and 
transferrin was labelled with Cy5-monofunctional reactive dye. Transiently transfected 
HeLa cells grown on coverslips at 37°C were incubated with Cy3-FGF1 for two hours 
at 4°C in the presence of 50 U/ml heparin in HEPES medium. The cells were then 
washed three times in PBS and incubated in DMEM with 0.3 mM leupeptin at 37°C 
for different periods of time. The cells were fixed in 3% paraformaldehyd in PBS for 
15 min, washed three times in PBS and mounted in Mowiol. In some cases the cells 
were also incubated with Alexa 488 EGF, Cy3-FGF and Cy5-transferrin in the 
presence of 50 U/ml heparin and 0.3 mM leupeptin. When antibodies were used to 
visualize structures within the cell, the fixation was quenched with 50 mM NH4Cl in 
PBS for 15 min and the cells were permeabilized with 0.05% saponin in PBS for 5 
min. The cells were then incubated with primary antibody in 0.05% saponin in PBS for 
20 min, washed three times in 0.05% saponin in PBS and incubated with the secondary 
antibody coupled to a fluorophore. After washing once in 0.05% saponin and twice in 
PBS, the cells were mounted in Mowiol and examined with a Zeiss LSM 510 META 
confocal microscope. Images were prepared with Adobe Photoshop 7.0 and Zeiss 
LSM Image Browser. 
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Quantification of colocalization 
Images of transfected, randomly chosen cells were divided into squares, and every 
fifth square within the chosen cell was examined. Red structures indicating 
internalized Cy3-labelled FGF1 were compared with structures of the different 
markers and the proportion of red structures that colocalized with structures of the 
specific marker was calculated. The mean and standard deviation were calculated from 
15 cells in each case. 
Degradation of internalized FGF1 
[35S]methionine-labelled 18 kDa, long form of FGF1 was produced by transcription 
from the pTriEX-2 plasmid using T7 RNA polymerase and translation in a rabbit 
reticulocyte lysate supplemented with Easytag Methionine L-[35S] according to the 
manufacturer’s protocol. HeLa cells, transiently transfected with the different FGFRs 
were incubated with [35S]methionine-labelled 18 kDa form of FGF1 and 20 U/ml 
heparin at 37°C for 30 min to allow endocytosis via high-affinity receptors. Then the 
cells were washed twice with a high salt, low pH buffer (1 M NaCl, 20 mM NaAc, pH 
4.0) and once with PBS on ice to remove excess and cell-surface bound FGF1. The 
cells were then either lysed immediately in lysis buffer (0.1 M NaCl, 10 mM 
Na2HPO4, 1% Triton X-100, 1 mM EDTA, supplemented with complete protease 
inhibitors, pH 7.4) or incubated further in growth medium with or without 100 µM 
chloroquine at 37°C for 3 or 6 h before lysis. [35S]methionine-labelled FGF1 was 
extracted from the lysate by adsorption to heparin-Sepharose and analysed by 15% 
SDS-PAGE as described by Laemmli20. The proteins on the gels were fixed in fixative 
(25% methanol, 7.5% acetic acid) and then the gels were dried. Phosphorimager 
scanning and Image Quant, Version 5.0 software were used to estimate the relative 
amount of radioactive FGF.  
Degradation of internalized receptors 
HeLa cells not transfected or transiently transfected with FGFR1, FGFR2, FGFR3 or 
FGFR4 were washed three times in PBS and cell-surface proteins were biotinylated 
with 0.5 mg/ml Ez-link sulfo-NHS-LC-Biotin in PBS for 15 min at 4°C. The 
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biotinylation reaction was quenched with 50 mM Tris-HCl pH 8.0. The cells were 
washed twice with PBS and then incubated for indicated periods of time in DMEM 
containing 100 ng/ml FGF1 and 20 U/ml Heparin. The cells were washed with PBS 
and lysed on ice in lysis buffer for 20 min. The lysate was centrifuged to remove 
nuclei and then biotinylated proteins were pulled down from the supernatant with 
streptavidin-Sepharose beads at 4°C over night. The beads were then washed three 
times in PBS containing 0.1% Tween 20 and finally resuspended in 15µl of reducing 
SDS-PAGE sample buffer. Proteins were separated by 7% SDS-PAGE and transferred 
to a PVDF membrane which was probed with anti-FGFR1, anti-FGFR2, anti-FGFR3 
or anti-FGFR4 primary antibodies and HRP-conjugated secondary antibody. 
Immunoactivity was detected by using ECL plus Western blotting system and Chemi 
Genius Image Acquisition System. To compare the intensity of bands of interest on the 
membrane, ImageQuant software was used. Background correction was performed by 
subtracting values obtained by scanning adjacent areas of the membrane with the same 
size but containing no visible bands from those obtained with the bands of interest. 
Ubiquitination of internalized receptors 
HeLa cells cotransfected with myc-ubiquitin and FGFR1, FGFR4 or empty vector 
were starved for 16 hours and then washed three times in PBS. Cell-surface proteins 
were biotinylated with 0.5 mg/ml Ez-link sulfo-NHS-LC-Biotin in PBS for 15 min at 
4°C. The biotinylation reaction was quenched with 50 mM Tris-HCl pH 8.0 and the 
cells were washed twice with PBS. The cells were incubated for two hours in 200 
ng/ml FGF1, 20 U/ml heparin and 0.3 mM leupeptin at 37°C in DMEM without 
serum. The cells were then washed once in DMEM without serum and lysed at 95°C 
for 5 min in 1% SDS in PBS. The lysate was decanted into QIAshredder columns and 
centrifuged two min at 4°C. Equal amounts of lysate and 2X pull down-buffer (2% 
Triton X-100, 0.5% sodium deoxycholate, 2 mM EDTA, 40 mM NaF, 1% bovine 
serum albumine, 2 mM N-ethylmaleimide supplemented with protease and 
phosphatase inhibitors) were added to streptavidin-Sepharose beads to pull down 
biotinylated proteins. After tumbling one hour at 4°C the beads were washed twice in 
1X pull-down buffer (0.5% SDS and 50% 2X pull-down buffer in PBS) once in 1:10 
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diluted PBS. The proteins that remained bound to the streptavidin-Sepharose beads 
were run on a 7% SDS-PAGE and then transferred to a PVDF membrane which was 
probed with anti-myc primary antibody and HRP-conjugated secondary antibody to 
detect the level of ubiquitination of internalized FGFRs. Immunoreactivity was 
detected using ECL plus Western blotting system and Chemi Genius Image 
Acquisition System. The membrane was stripped twice and reprobed with anti-
phospho FGFR primary antibody and HRP-conjugated secondary antibody to detect 
the level of internalized receptors and anti-transferrin receptor primary antibody and 
HRP-conjugated secondary antibody to verify equal loading of the gel. To ensure 
equal expression of ubiquitin, the cells were analysed by immunofluorescence 
microscopy. 
Results 
Characterization of the endocytic pathway followed by FGF1/FGFR1-4 
Upon ligand binding to the high-affinity FGF receptors, the ligand-receptor complexes 
are internalized27,35 and transported to various intracellular compartments. Since FGF1 
binds equally well to the four high-affinity FGF receptors29, we have chosen this as a 
ligand and labelled it with the fluorescent dye Cy3. The fluorescent growth factor was 
used as a marker to explore the intracellular trafficking of the receptors. Cy3-labelled 
FGF1 has previously been shown to retain its binding capacity towards the FGFRs and 
HSPGs6.  
The distribution of fluorescent growth factor-receptor complexes was studied in HeLa 
cells transiently transfected with the different high-affinity receptors and incubated 
with Cy3-FGF1 for different periods of time. HeLa cells do not express detectable 
amounts of endogenous FGFRs. To avoid FGF1 binding to cell-surface heparan 
proteoglycans and to facilitate binding to the high-affinity FGFRs, heparin was added 
to the extracellular medium. The data in Figure 1 demonstrate that fluorescent FGF1 
binds exclusively to the surface of transfected cells when treated with the growth 
factor at 4°C in the presence of heparin. When the cells were subsequently incubated 
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Figure 1. Binding of FGF1 to cell-surface FGFRs. HeLa cells were transiently transfected with FGFR1, 2, 3 or 
4 and incubated with Cy3-labelled FGF1 and 20 U/ml heparin for two hours at 4°C.  The cells were then fixed 
and examined by confocal microscopy. The red channel image was superimposed onto the corresponding 
interference contrast image. Scale bar, 5 µm. 
at 37°C, the amount of growth factor at the surface was reduced and the fluorescent 
growth factor appeared as intracellular dots, indicating uptake into vesicles (Figure 2). 
To determine whether FGF1 and the different FGFRs remain in the same 
compartments after internalization, we carried out double-labelling experiments where 
cells were allowed to take up Cy3-labelled growth factor for 2 h at 37°C in the 
presence of leupeptin (an inhibitor of lysosomal degradation) and then stained with 
antibodies against the different FGFRs. As shown in Figure 2, there was considerable 
overlap between internalized FGF1 and the specific fluorescent FGFR staining. This 
was demonstrated in the overlay experiments when spots labelled with both 
fluorophores appeared yellow. This finding indicates that the internalized growth 
factor remains bound to the receptor during the endocytic pathway as previously 
reported for FGF7/FGFR21,22 and FGF1/FGFR46. 
To follow the endocytic pathway and to identify the intracellular structures where the 
different FGF1/FGFR complexes are localized upon internalization, the transiently 
transfected HeLa cells were allowed to bind Cy3-labelled FGF1 at 4°C and they were 
then incubated for different periods of time at 37°C. The cells were then fixed and 
stained with markers for different intracellular compartments. As shown in Figure 3, 
incubation for 15 min at 37°C resulted in good overlap of EEA1, a protein associated 
with early/sorting endosomes26, and endocytosed Cy3-FGF1. Quantification of  
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Figure 2. Localization of FGFRs and endocytosed FGF1. HeLa cells, transiently transfected with FGFR1, 2, 3 
or 4 were incubated with Cy3-FGF1, 20 U/ml heparin and 0.3 mM leupeptin for two hours at 37°C. The cells 
were then fixed, permeabilized and treated with rabbit anti-FGFR1, anti-FGFR2, anti-FGFR3 or anti-FGFR4 
primary antibodies. The cells were further treated with Cy2-conjugated anti-rabbit secondary antibodies and 
examined by confocal microscopy. Arrows point to colocalization. Scale bar, 5 µm. 
colocalization revealed that the degree of overlap between the two fluorescent signals 
was similar for all the four high-affinity receptors, indicating that internalized 
FGF1/FGFR complexes reach the sorting endosomal compartment irrespective of 
receptor type (Figure 3B).  
After a 2 h chase in the presence of leupeptin the major part of the internalized FGF1 
in cells transfected with FGFR1-3 was found to colocalize with LAMP-1, a marker for 
late endosomes/lysosomes10, while FGF1 in FGFR4 transfected cells was not (Figure 
4A). About 90% of the FGF1 positive structures in FGFR1 transfected cells were 
LAMP-1 positive, whereas only around 45% of the FGF1 positive structures in cells  
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Figure 3. Localization of EEA1 and endocytosed FGF1. (A) HeLa cells were transiently transfected with 
FGFR1, 2, 3 or 4 and incubated with Cy3-FGF1 and 20 U/ml heparin for two hours at 4°C. The cells were 
washed and further incubated in the presence of 0.3 mM leupeptin for 15 min at 37°C. The cells were fixed 
immediately, permeabilized and treated with mouse anti-EEA1 primary antibody. The cells were further treated 
with Cy2-conjugated anti-mouse secondary antibody and examined by confocal microscopy. Arrows point to 
colocalization. Scale bar, 5 µm. (B) The percentage of FGF1 positive structures within cells transfected with 
FGFR1, 2, 3 or 4 that colocalizes with EEA1 was quantified as described in materials and methods. Error bars 
denote the standard deviation, n=15 
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Figure 4. Localization of LAMP-1 and endocytosed FGF1. (A) HeLa cells were transiently transfected with 
FGFR1, 2, 3 or 4 and incubated with Cy3-FGF1 and 20 U/ml heparin for two hours at 4°C. The cells were 
washed and further incubated in the presence of 0.3 mM leupeptin for two hours at 37°C. The cells were fixed 
immediately, permeabilized and treated with mouse anti-LAMP-1 primary antibody. The cells were further 
treated with Cy2-labelled anti-mouse secondary antibody and examined by confocal microscopy. Arrows point 
to colocalization or lack of colocalization. Scale bar, 5 µm. (B) The percentage of FGF1 positive structures 
within cells transfected with FGFR1, 2, 3 or 4 that colocalizes with LAMP-1 was quantified as described in 
materials and methods. Error bars denote the standard deviation, n=15. 
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transfected with FGFR4 were LAMP-1 positive (Figure 4B). In the case of FGFR2 and 
3 around 70% of the FGF1 positive structures were also positive for LAMP-1. These 
findings indicate that subsequent to their presence in early/sorting endosomes the four 
FGF receptors are sorted differently and that the major part of internalized FGFR1-3 is 
sorted to lysosomes while the major part of internalized FGFR4 is not. 
In attempts to further assess the different sorting of the receptors and to decide the 
localization of FGF1/FGFR4 complex subsequent to its presence in early/sorting 
endosomes, the endocytic pathway followed by the fluorescent FGF1 together with the 
different FGF receptors was compared with the pathways taken by epidermal growth 
factor (EGF) and transferrin. The most comprehensive studies of tyrosine kinase 
receptor endocytosis have been carried out using the EGF receptor as an experimental 
model, demonstrating that the EGFR and its ligand progress to lysosomes upon 
internalization9. On the other hand, the transferrin receptor and its ligand are known to 
be recycled from early/sorting endosomes via the endosomal recycling compartment 
back to the cell surface16.  
HeLa cells transfected with the different FGF receptors were incubated for 2 h at 37°C 
with Alexa 488 labelled EGF and Cy3-labelled FGF in the presence of leupeptin. Cy5-
labelled transferrin was added after 90 min. Colocalization was demonstrated in 
overlay experiments when spots labelled with Cy3-FGF1 and alexa 488 EGF appeared 
yellow and spots labelled with Cy3-FGF1 and Cy5-transferrin appeared purple. 
Consistent with previous findings, fluorescent FGF1 endocytosed by FGFR1-3 showed 
considerable overlap with fluorescent EGF, indicating that the major part of 
internalized FGF1/FGFR1-3 complexes accumulates in lysosomes. On the other hand, 
fluorescent FGF1 endocytosed by FGFR4 showed a notable overlap with transferrin,  
Figure 5. Localization of endocytosed EGF, transferrin and FGF1. (A) HeLa cells were transiently 
transfected with FGFR1, 2, 3 or 4 and incubated for two hours at 37°C with Cy3-FGF1 and Alexa488-EGF in 
the presence of 20 U/ml heparin and 0.3 mM leupeptin. Cy5-transferrin (Tf) was added after 90 min. The cells 
were fixed and examined by confocal microscopy. Arrows point to colocalization or lack of colocalization. Scale 
bar, 5 µm. (B) The percentage of FGF1 positive structures within cells transfected with FGFR1, 2, 3 or 4 that 
colocalize with EGF, Tf, neither EGF nor Tf or both EGF and Tf was quantified as described in materials and 
methods. Error bars denote the standard deviation, n=15. 
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indicating that a great part of the internalized FGF1/FGFR4 complexes accumulate in 
the endocytic recycling compartment (Figure 5A). 
Quantification of colocalization was performed as described in materials and methods. 
As shown in Figure 5B approximately 65% of the FGF1 positive structures in cells 
transfected with FGFR1 colocalized with intracellular structures containing EGF, 
while only around 8% of the FGF1 positive structures colocalized with intracellular 
structures containing transferrin.  In cells transfected with receptor 2 or 3 between 40 
and 50% of the FGF1 positive structures also contained EGF, while about 20% of the 
FGF1 positive structures contained transferrin. In the case of cells transfected with 
FGFR4 only around 20% of the FGF1 positive structures contained EGF, while around 
50% of the FGF1 positive structures contained transferrin. Noteworthy, between 20 
and 30% of the FGF1 positive structures in the transfected cells did not contain EGF 
nor transferrin and a small fraction of around 5% of the FGF1 positive structures 
contained both EGF and transferrin. 
Degradation of internalized FGF1 and FGFRs 
We then considered the possibility that the different sorting of the four related FGFRs 
could results in different kinetics of degradation. To study this, the degradation of 
FGF1 internalized by the four FGF receptors was analysed in FGFR-transfected HeLa 
cells.  
The cells were incubated with radiolabelled 18 kDa form of FGF1 for 30 min to allow 
endocytosis of the growth factor/receptor complex to occur. The cells were then 
washed to remove surface-bound FGF1 and further incubated for the indicated periods 
of time. Finally, the cells were lysed and solubilized proteins were adsorbed to 
heparin-Sepharose and analysed by SDS-PAGE. The degradation of FGF1 can be seen 
in Figure 6A as a stepwise conversion of the 18 kDa form of FGF1 into the shorter 16 
kDa form followed by further degradation.  
Further degradation of FGF1 seems to occur more slowly, indicating that the shorter 
form of FGF1 is more resistant to degradation than the 18 kDa form of FGF1.  
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Figure 6. Degradation of endocytosed long form of FGF1 (18 kDa). (A) HeLa cells, transiently transfected 
with FGFR1, 2, 3 or 4 were incubated with [35S]methionine-labelled, 18 kDa form of FGF1 and 20U/ml heparin 
at 37°C for 30 min to allow endocytosis via high affinity receptors. The cells were then either lysed immediately 
(0h) or incubated further in growth medium with or without chloroquine at 37°C for 3 or 6 hours before lysis. 
[35S]methionine-labelled FGF1 was extracted from the lysate by binding to heparin-Sepharose and analysed by 
SDS-PAGE. (B) For each receptor the amount of the 18 kDa form of FGF1 was calculated at each time point and 
expressed as a percentage of the amount of the 18 kDa form of FGF1 at time point 0. Values are averages of 5 
independent experiments for FGFR1 and FGFR4 and 3 independent experiments for FGFR2 and FGFR3. Error 
bars denote the standard deviation. 
Degradation of internalized FGF1 was inhibited by the weak base chloroquine (shown 
only for FGFR1), suggesting that the digestion occurred in a lysosomal compartment.  
After 6 hours only a small fraction of FGF1 remained as the 18 kDa form in cells 
transfected with FGFR1, whereas a significant amount of the 18 kDa form of FGF1 
was detected in cells transfected with FGFR4. The amount of the 18 kDa form of 
FGF1 that remained in the cells was calculated for each receptor type and each time 
point, and expressed as a percentage of the amount of the 18 kDa form of FGF1 at 
time point 0. The values plotted in the graph in Figure 6B are average values from 5 
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(for FGFR1 and FGFR4) and 3 (for FGFR2 and FGFR3) independent experiments. 
Approximately 50% of the FGF1 exist as the 18 kDa form in FGFR4 transfected cells 
after 3 hours, whereas only 15% of the FGF1 remained as the 18 kDa form after 3 
hours in cells transfected with FGFR1. The amount of the 18 kDa form of FGF1 in 
cells transfected with FGFR2 or FGFR3 was reduced to about 30% after 3 hours. 
These results show that FGF1 endocytosed via FGFR4 are more slowly degraded than 
FGF1 endocytosed via FGFR1. FGF1 endocytosed via FGFR2 or 3 seems to be more 
slowly degraded than FGF1 endocytosed via FGFR1, but faster than FGF1 
endocytosed via FGFR4. 
To analyse the degradation of internalized receptors, biotinylation of cell-surface 
proteins was carried out on cells transfected with the different FGF receptors. The cells 
were then stimulated with FGF1 for indicated periods of time and the biotinylated 
proteins in the collected lysates were pulled down with streptavidin-Sepharose 
followed by immunoblotting with appropriate receptor antibodies. Gradual 
disappearance of the bands in the immunoblots corresponding to the receptors 
demonstrates degradation of the internalized receptors (Figure 7). The decreased 
intensity of the bands revealed that internalized FGFR1 was efficiently degraded after 
2 hours whereas the amount of internalized FGFR4 was only slightly decreased after 6 
hours. The degradation of FGFR2 and FGFR3 seem to occur slower than the 
degradation of FGFR1 but considerable faster than FGFR4.  
The amount of FGFRs that remained in the cells was calculated for each receptor type 
and each time point, and expressed as a percentage of the amount of receptors at time 
point 0. The mean values from three independent experiments plotted in the graph in 
Figure 7B demonstrate a decrease in the amount of FGFR1 from 100 to ~15% in two 
hours whereas the amount of receptor 4 was decreased to ~80% in six hours. In the 
case of FGFR2 and FGFR3 30-40% of the receptors were detectable after 6 hours. 
These findings indicate that FGFR4 are more slowly degraded than FGFR1. FGFR2 
and FGFR3 seem to be more slowly degraded than FGFR1, but faster degraded than 
FGFR4. These data together with the results in Figure 6 support the previous findings 
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Figure 7. Degradation of endocytosed FGFRs. (A) Cell surface proteins on HeLa cells, not transfected (NT) or 
transiently transfected with FGFR1, 2, 3 or 4 were biotinylated and the cells were incubated for the indicated 
periods of time at 37°C in the presence of 100 ng/ml FGF1 and 20 U/ml heparin. Biotinylated proteins from 
lysed cells were adsorbed to streptavidin Sepharose and analysed by immunoblotting (IB) with appropriate anti-
FGFR antibodies. (B) The intensity of the bands at time point zero was set to 100% and the relative amount of 
receptors at each time point was measured. Values are averages of three independent experiments. Error bars 
denote the standard deviation. 
that the major part of FGF1 endocytosed together with receptor 4 recycles, whereas the 
major part of FGF1 internalized by receptor 1, 2 and 3 accumulates in lysosomes. 
Ubiquitination of internalized FGFRs 
The attachment of ubiquitin to the intracellular part of a membrane protein is thought 
to function as a signal for lysosomal degradation14,33. If ubiquitination is responsible 
for the observed different sorting of the FGF receptors, one would expect FGFR4 to 
become less ubiquitinated than FGFR1. An amino acid sequence alignment of the 
intracellular part of the four receptors revealed several lysines conserved in FGFR1-3 
that were absent in FGFR4 (Figure 8). The intracellular part of receptor 1 and 2 
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Figure 8. Amino acid sequence alignment of the intracellular part of FGFR1-4. The amino acid sequence 
alignment of the intracellular part of FGFR1, FGFR2, FGFR3 and FGFR4 was created using the Vector NTI 9.0 
software based on a Clustal W algorithm36. The protein sequences were obtained from the following DNA 
sequences at NCBI; M34641, BC039243, NM_000142 and X57205. A dash represents a gap introduced to 
optimize the alignment. Lysines conserved in all the four receptors are indicated in light grey while other lysines 
are indicated in dark grey. 
contain 29 lysines, the intracellular part of FGFR3 contains 25 lysines whereas only 16 
lysines were found in the intracellular domain of FGFR4. This finding suggested that 
the level of ubiquitination might be the reason for the different sorting of the receptors. 
To investigate whether internalized FGFR4 is less ubiquitinated than internalized 
FGFR1, HeLa cells co-expressing the myc-tagged ubiquitin and either FGFR1, FGFR4 
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Figure 9. Ubiquitination of endocytosed FGFRs.  
HeLa cells were cotransfected with myc-ubiquitin and 
FGFR1, FGFR4 or the empty vector (pcDNA3) and 
starved over night. Cell-surface proteins were 
biotinylated and the cells were incubated for indicated 
periods of time at 37°C in the presence of 200 ng/ml 
FGF1 and 20 U/ml heparin. Biotinylated proteins from 
lysed cells were adsorbed to streptavidin Sepharose and 
analysed by immunoblotting (IB) with anti-myc 
antibodies. The membrane was stripped and reprobed 
with anti-phospho FGFR antibodies (anti-pFGFR) and 
anti-transferrin receptor antibodies (anti-TfR). 
or an empty vector were starved over night. The starvation was included to avoid 
stimulation and possibly ubiquitination of other surface proteins by factors in the 
serum.  
Cell-surface proteins were then biotinylated and stimulated with FGF1 for 2 hours. 
Leupeptin was added to prevent lysosomal degradation of the receptors. The cells were 
then lysed and biotinylated proteins were pulled down and analysed by western 
blotting using anti-myc antibody (Figure 9). Ubiquitination of both FGFR1 and 
FGFR4 was detected as a smear of bands migrating more slowly than the receptors as 
such. The signal was much stronger for FGFR1 than for FGFR4, indicating that 
FGFR1 is more ubiquitinated. Very little ubiquitination was detected in cells 
transfected with the empty vector.  
Equal amount of the FGFRs on the membrane was verified by membrane stripping and 
reprobing with an anti-phospho FGFR antibody that is raised by immunizing rabbits 
with a synthetic peptide corresponding to residues surrounding tyrosine 653/654 of 
human FGFR1, which are conserved in FGFR1, 2, 3 and 4. The results indicate that 
similar amounts of FGFR1 and FGFR4 were analysed (Figure 9). To test for equal 
loading on the gel, the membrane was stripped and reprobed with anti-transferrin 
receptor antibodies. The bands were about equally strong in each case (Figure 9). 
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Equal expression of the myc ubiquitin construct was confirmed by 
immunofluorescence microscopy (data not shown).  
Alltogether, the observations demonstrate that FGFR4 is less ubiquitnated than FGFR1 
and they suggest that the different levels of ubiquitination are the molecular 
mechanism determining their different sorting. 
Discussion 
In order to compare the intracellular trafficking of FGF1 endocytosed by the four 
related FGFRs, transiently transfected HeLa cells which do not express detectable 
amounts of endogenous FGFRs were chosen as a model system. The present work 
demonstrates that FGF1 internalized by FGFR1, FGFR2 and FGFR3 are targeted for 
lysosomal degradation whereas the majority of FGF1 internalized by FGFR4 escapes 
into a recycling pathway. Furthermore, FGF1 endocytosed by FGFR4 was more 
slowly degraded than FGF1 endocytosed by FGFR1, 2 or 3. Also, FGFR4 itself was 
more slowly degraded than the other receptors. 
Targeting of receptors for lysosomal degradation has been associated with 
ubiquitination of the intracellular part of the receptors. Consistent with the observed 
different sorting of the FGFRs, FGFR4 seems to be less ubiquitinated than FGFR1. 
This indicates that different levels of ubiquitination of the FGFRs might define their 
intracellular sorting. 
The present findings are in accordance with previous data concerning the trafficking of 
endocytosed FGFRs. KGF/KGFR (FGF7 and a splicing variant of FGFR2) in HeLa 
cells and FGF2/FGFR3 in RCJ cells has previously been reported to enter the 
lysosomes upon internalization1,4 and internalized FGF1/FGFR4 was found to 
accumulate in the recycling compartment in COS cells6. It has also been reported that 
binding of FGF to FGFR1 in HeLa cells40 and PAE cells24 and binding of FGF to 
FGFR3 in COS-7 cells4 and 293T cells23 induces ubiquitination of the receptors and 
that this contributes to their downregulation. Taken together these findings indicate 
that the distinct sorting of the FGF receptors is dependent on receptor type rather than 
cell type. 
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The juxtanuclear localization of FGF1/FGFR4 previously described in COS cells5,6, 
was not observed in HeLa cells, although the major part of the receptors seems to 
localize to the endocytic recycling compartment in both cases. This could simply be 
explained by morphological differences between the two cell lines. In some cell types, 
the endocytic recycling compartment is concentrated near the centriole, whereas the 
compartment is distributed more widely throughout the cytoplasm in others21. The 
more wide distribution of the endocytic recycling compartment in HeLa cells made it 
easier to quantify the different trafficking of the receptors by laser scanning confocal 
microscopy. 
Late endosomes and lysosomes contain large amounts of glycoproteins such as 
lysosomal-associated membrane protein-1 (LAMP-1)10. The staining of these 
compartments for laser scanning confocal microscopy analysis with primary 
antibodies against LAMP-1 and fluorophore-conjugated secondary antibodies gave a 
dense pattern of LAMP-1 positive structures. The dense pattern may have caused an 
overestimation of the degree of colocalization between FGF1 positive structures and 
LAMP-1 positive structures. In FGFR4 transfected cells approximately 45% of the 
FGF1 positive structures were positive for LAMP-1. However, when the distribution 
of fluorophore-labelled FGF1 internalized via FGFR4 was compared with the 
distribution of internalized fluorophore-labelled EGF, a marker for lysosomal 
trafficking, only 20% of the FGF1 positive structures contained EGF. 
When continuous uptake of fluorophore-labelled FGF1 was allowed in cells 
transfected with the different receptors, between 20 and 30% of the FGF1 positive 
structures inside the cells colocalized neither with the marker for lysosomal trafficking 
(EGF) nor the marker for the recycling pathway, transferrin. It is likely that the amount 
of overexpressed FGFRs exceeds the amount of the other receptors at the cell surface. 
Therefore, free FGFRs could still be present at the cell surface, ready to bind ligand 
and internalize when most of the EGF and transferrin receptors are already located in 
intracellular vesicles. Some of the FGF1 positive structures inside the cells also 
contained both fluorophore labelled EGF and transferrin. Since EGF and transferrin 
are known to enter early endosomes upon internalization, it is not surprising that some 
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intracellular vesicles contained both ligands when continuous uptake of ligands was 
allowed. 
The degradation of internalized FGF1 was seen as a stepwise conversion of the 18 kDa 
form of FGF1 into a shorter 16 kDa form. Further degradation of the short form of 
FGF1 seemed to occur more slowly, indicating that the shorter form of FGF1 is more 
resistant to degradation than the long form of FGF1. Internalized FGF2 in BCE cells 
have been reported to be rapidly cleaved from an 18 kDa form to a 16 kDa form and 
the 16 kDa form was then found to be more slowly degraded with a half-life of 
approximately 8 hours25. This seems to be the case for FGF1 as well. 
The kinetics of FGFR degradation has been addressed in a few studies1,4,35. Common 
for these studies are metabolical labelling of cells, followed by immunoprecipitation of 
the FGFRs and analysis of the relative amount of the remaining FGFRs by 
autoradiography. This approach was not suitable for our purposes as a considerable 
amount of overexpressed proteins seems to be degraded at the endoplasmic reticulum 
(ER). In a metabolic labelling pulse chase experiment recently reported34, about 60-
80% of the FGFR4 was degraded after 4 hours when cells overexpressing the receptor 
were treated with brefeldin A to inhibit transport out of the ER. Even though the 
degradation in the ER probably was increased as the transport out of the ER was 
blocked, this experiment indicates that a considerable amount of the overexpressed 
receptors is degraded in the ER. In our report the detection of lysosomal receptor 
degradation was ensured by the extraction of biotinylated cell-surface proteins. Ligand 
independent degradation of metabolically labelled FGFR1 and FGFR2 has also been 
reported1,35. This could be explained partly by ER degradation due to receptor 
overexpression, but not totally as the cells used in the case of FGFR1 were stably 
transfected. It is therefore not excluded that a constitutive turnover of the receptors 
from the cell surface takes place. 
All the four FGFRs have been found to have distinct patterns of distribution in many 
human tissues. The most widespread expression has been observed for FGFR1 
whereas FGFR4 was found to have a more limited distribution17. FGFR mouse gene 
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knockout and mutational studies have implicated FGFR1-3 in numerous 
developmental events while FGFR4 seems to play a more modest role in 
developmental processes12,28,41. It is possible that the limited function in developmental 
events and the restricted distribution of FGFR4 could be explained by the different 
sorting of the FGFRs. The recycling of FGFR4 might prolong its signalling activities 
and the signalling might be further prolonged if the ligands internalized by FGFR4 are 
allowed to reappear at the cell surface and activate new FGFRs. It is therefore likely 
that FGFR4 is less involved in processes where accurate downregulation of signalling 
receptors is necessary. However, the recycling of FGFR4 may on the other hand 
provide a mechanism for gradient formation during developmental processes. A 
simple model of gradient formation postulates that morphogens dilute as they diffuse 
between cells. Recent data supports the idea that movement of morphogens could also 
occur by vesicular trafficking through the cells8. Recycled morphogens can thus be re-
secreted and move forward into the target tissue. FGFs could therefore after binding 
and activation of FGFR4 in one cell, be recycled and activate neighbouring cells and 
spread through the tissue. 
FGFRs have been found overexpressed or mutated to constitutively active forms in 
several human cancers30. It might be suggested that elevated levels or constitutively 
active forms of FGFR4, to a greater extent than the other FGFRs, predisposes cancer 
patients for accelerated disease progression because they are not efficiently 
downregulated. On the other hand, examination of constitutively activated derivatives 
of FGFR1, FGFR3 and FGFR4 in which a myristylation signal was substituted in 
place of the extracellular and transmembrane domains, thereby targeting the kinase 
domain to the plasma membrane, revealed that FGFR4 was much less transforming 
than activated FGFR1 and FGFR315. Since FGFR1 also exhibit higher signalling 
activity than FGFR4 it has been suggested that FGFR1 is the most potent mutagenic 
member of the FGFR family37,38. Other mechanisms for attenuating signals may 
therefore play a role to limit the signalling from the FGFR4 that is less efficiently 
degraded. 
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Although the exact biological role of the different trafficking of the FGF receptors 
remains to be revealed, further studies on the basic biology of FGFs, FGFRs and their 
signalling is of importance. Knowledge about how the growth factors and their 
corresponding receptors function is crucial in order to try to stimulate or inhibit their 
effects for possible therapeutic purposes. 
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